Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 3, 2026
Here is an uncomfortable fact about the standard cardiovascular workup most adults receive: it can come back clean — total cholesterol fine, LDL fine, blood pressure fine — while missing a risk factor that roughly one in five people carry, that triples or quadruples lifetime risk of heart attack and aortic valve disease in those who have it, and that you only need to measure once in your entire…
This dispatch covers There's a Genetic Cardiovascular Risk Marker in 1 of 5 People — and It's Probably Not on Your Last Blood Panel in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 10 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Here is an uncomfortable fact about the standard cardiovascular workup most adults receive: it can come back clean — total cholesterol fine, LDL fine, blood pressure fine — while missing a risk factor that roughly one in five people carry, that triples or quadruples lifetime risk of heart attack and aortic valve disease in those who have it, and that you only need to measure once in your entire life.
The marker is lipoprotein(a), written Lp(a) and pronounced "L-P-little-a." It is one of the most strongly evidence-backed, genetically determined cardiovascular risk factors known to medicine. Every major cardiology society — the American Heart Association, the American College of Cardiology, the European Atherosclerosis Society, the National Lipid Association — now recommends measuring it at least once in every adult. And yet in routine practice it is almost never ordered. Most people reading this have had a "cholesterol check" and have no idea what their Lp(a) is, because it was never on the panel.
This article explains what Lp(a) is, why it matters, why it falls through the cracks, and what the current science says about who should know their number. It is educational and not medical advice — but by the end you will understand why this single value belongs on a thorough panel and why "your cholesterol looks good" is not the same thing as "your cardiovascular risk is fully assessed."
To understand Lp(a), start with LDL — the particle most people know as "bad cholesterol." LDL ferries cholesterol through the bloodstream, and when there are too many LDL particles, they can lodge in artery walls and seed plaque.
Lp(a) is, structurally, an LDL particle with an extra protein bolted onto it: a molecule called apolipoprotein(a), or apo(a), wound around the standard apolipoprotein B that every LDL particle carries. That single addition changes its behavior. Lp(a) is more prone to depositing in artery walls, it promotes inflammation, it carries oxidized phospholipids that accelerate plaque formation, and it appears to interfere with the body's clot-dissolving machinery — nudging the system toward clotting. In effect, it combines a cholesterol-delivery problem with a pro-inflammatory and pro-clotting problem in one particle.
Three large bodies of evidence built the case that this is causal, not just correlational:
That convergence — epidemiology, genetics, and mechanism all pointing the same direction — is why cardiology has moved Lp(a) from "interesting research marker" to "measure it in everyone."
Here is the feature that makes Lp(a) different from almost every other number on a blood panel: it is roughly 80–90% genetically determined, set by the gene you inherited, and it stays remarkably stable across your life. Your LDL responds to diet, exercise, weight, and medication. Your fasting glucose swings with last night's dinner. Your Lp(a) does essentially none of that. A healthy 25-year-old and the same person at 55 will, in most cases, have a similar Lp(a) — barring a few specific influences like kidney disease, certain hormonal shifts, and inflammation states.
Two practical consequences follow.
First, you only need to measure it once. Because the value is stable, a single lifetime measurement tells you whether you carry elevated Lp(a). That is genuinely unusual in laboratory medicine and it is exactly why the guideline language is "once in a lifetime." It is a low-cost, high-information, one-time test.
Second, a normal LDL does not rule out high Lp(a), and vice versa. They are partly independent. You can have textbook-perfect standard cholesterol and still carry an Lp(a) in the top fifth of the population. This is precisely how the standard panel misses it: the doctor sees a clean lipid panel, concludes the cardiovascular box is checked, and never orders the one test that would have revealed the inherited risk sitting underneath.
Roughly 20% of the global population — about one in five people — has an Lp(a) level high enough to meaningfully raise cardiovascular risk. That is not a rare-disease frequency. It is more common than type 2 diabetes. The prevalence and the typical levels also differ across ancestry: people of South Asian and of African descent tend, on average, to carry higher Lp(a), which matters for how seriously a "normal-looking" panel should be trusted in those groups.
Several patterns should raise the index of suspicion that elevated Lp(a) is in play:
But the deeper point is that you do not need any of these flags to justify measuring it. The guidelines recommend testing every adult once precisely because the inherited risk is silent until it isn't.
Lp(a) is a simple blood draw — no fasting strictly required for the test itself, and it can run alongside a standard lipid panel. The complication is that laboratories report it in two different units, and the two are not interchangeable:
The current scientific preference is nmol/L, because Lp(a) particles vary in size and a mass-based measure can mislead. There is no clean universal conversion between the two — the relationship depends on particle size — so the unit on your report matters when interpreting it.
As a broad orientation to the thresholds most commonly cited in the literature (this is for understanding, not self-diagnosis):
| Lp(a) level (nmol/L) | General interpretation |
|---|---|
| Below ~75 nmol/L | Generally considered low / desirable |
| ~75–125 nmol/L | Intermediate — a yellow flag in context |
| Above ~125 nmol/L | Elevated — associated with materially higher risk |
| Very high (≥ ~200+ nmol/L) | Among the strongest single-marker risk signals on a panel |
(In mg/dL, the commonly cited elevated threshold sits around 50 mg/dL and above, but the unit caveat applies.)
The exact cutoffs vary modestly between guidelines, and risk is continuous rather than a switch that flips at one number — but the orders of magnitude are what matter. Someone in the very-high band is carrying a genuinely different lifetime risk profile than someone near the floor.
The most common objection to measuring Lp(a) — even from clinicians — is that there has historically been no approved therapy that lowers it directly, so why measure something you can't treat? This reasoning is both outdated and, frankly, backwards.
It is outdated because Lp(a)-lowering therapies are now in advanced clinical trials, with large outcome studies underway to determine whether pharmacologically reducing Lp(a) reduces cardiovascular events. The field is moving quickly, and knowing your number now positions you to act if and when those therapies arrive.
It is backwards because knowing your Lp(a) changes meaningful decisions today, even without a drug aimed at the marker itself:
The notion that a test is only worth running if a pill follows directly from it ignores how much of cardiovascular prevention is about quantifying total risk and then pulling every available lever harder. Lp(a) is one of the highest-information, lowest-cost inputs into that calculation.
Regular readers of the Dispatch will recognize the pattern. Lp(a) joins a growing list of markers that are well-validated, decision-relevant, and routinely absent from the standard workup — ApoB for atherogenic particle count, fasting insulin for years-early metabolic dysfunction, homocysteine, GGT, ferritin. None of these are exotic. All of them are measurable. The common thread is that a "normal" basic panel creates a false sense of completeness, and the markers that would actually refine the picture never get ordered.
Lp(a) may be the cleanest example of the whole problem, because it asks so little: one draw, once, for a number that one in five people will be glad — or sobered — to know. The cost of measuring it is trivial. The cost of an inherited cardiovascular risk that goes unmeasured for thirty years is not.
Lp(a) is a genetically set, lifelong cardiovascular risk marker carried by roughly one in five people, recommended by every major cardiology society for once-in-a-lifetime measurement in all adults, and still almost never ordered in routine care. A clean standard cholesterol panel does not rule it out. You only need to measure it once. And knowing your number meaningfully sharpens how aggressively you and a clinician approach the risk factors you can change — and gives your family a reason to check theirs.
If you have never seen this value on a lab report, that is not because it doesn't apply to you. It is because it was never measured. A complete cardiovascular picture includes it.
This article is educational and is not medical advice. Lp(a) interpretation, cardiovascular risk assessment, and any treatment decisions should be made with a qualified clinician who can evaluate your individual history, family history, and full lab picture. A thorough metabolic and cardiovascular panel — including markers most standard checkups omit — is the starting point for understanding where you actually stand.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.